Prostatic Urethral Lift (PUL/UroLift) — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Blue Cross Blue Shield of North Carolina coverage for prostatic urethral lift (PUL/UroLift) procedures for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), including indications, limitations, and coding guidance for providers.
When Covered section updated to change prostate gland volume threshold from ≤80 cc to ≤100 cc and removed requirement about absence of obstructive or protruding median lobe.
When Covered section updated to change 'prostate gland volume is estimated to be ≤80 cc' to read 'Prostate gland volume is estimated to be ≤ 100 cc'.
Removed 'Prostate anatomy demonstrates normal bladder neck without an obstructive or protruding median lobe' from When Covered section.
Policy Guidelines updated and references updated on multiple review dates.
Coverage Criteria for Prostatic Urethral Lift (PUL/UroLift)
When Prostatic Urethral Lift is covered
Covered when ALL of the following are met:
When Prostatic Urethral Lift is not covered
When Covered (excerpt)
Policy 'When Covered' criteria were updated as noted below
Revised from ≤ 80 cc
Repeat prostatic urethral lift (PUL) procedures, PUL performed after other minimally invasive BPH procedures (for example, transurethral water vapor therapy), PUL performed in patients with a diagnosis of prostate cancer or who have been previously treated for prostate cancer, and use of more than 7 implants are considered investigational and are not covered. Use of PUL in any situation that does not meet the stated coverage criteria is considered investigational.
The policy update removed the prior anatomic exclusion requiring that the prostate demonstrate a normal bladder neck without an obstructive or protruding median lobe from the When Covered criteria. This change means the specific exclusion related to an obstructive or protruding median lobe is no longer listed in the When Covered section.
The policy states that use of PUL in situations not meeting the specified coverage criteria is considered investigational (not medically necessary). Examples explicitly identified as investigational include repeat PUL, PUL after other minimally invasive BPH procedures, PUL in patients with current or prior prostate cancer, and use of >7 implants.
The provided document excerpt does not present a separate, explicit list labeled “Not Medically Necessary.” Instead, the policy language and implementation notes state that uses not meeting the When Covered criteria are investigational; the update log documents revisions to the When Covered criteria but does not add a distinct Not Medically Necessary section in the excerpt shown.
Billing and Coding
| affected codes | placeholder noted where prior authorization/affected codes would be listed in policy |
Provider Actions, Prior Authorization & Documentation
Obtain prior authorization and use listed codes
Prior authorization may be required for PUL; when requesting coverage use the policy-listed applicable codes and ensure documentation demonstrates that all coverage criteria are met.
Confirm benefits/eligibility and be prepared to submit records
Benefits and eligibility are determined prior to application of medical guidelines; BCBSNC may require medical records to determine medical necessity before coverage is approved.
- Coverage determination depends on member’s contract and eligibility at time of service
Document prior trial of medical therapy (alpha‑1 and/or 5α‑reductase)
Document an appropriate trial of medical therapy before PUL: at least 1 month after an alpha-1-adrenergic antagonist or 3 months after a 5α-reductase inhibitor, unless the patient is intolerant or has contraindications.
- Record medication name(s), dose, start and stop dates, response, and reason for discontinuation if intolerant
- If combination therapy or other agents were used, document duration and clinical rationale
Document all coverage criteria elements
Ensure all required clinical criteria are documented to support medical necessity, including age, prostate volume, prior therapy trial, cancer exclusion testing, nickel allergy status, and physician training in PUL.
- Age documented ≥45 years
- Prostate gland volume estimated and recorded (≤100 cc) with measurement method
- Evidence of testing to exclude prostate cancer
- Statement regarding absence of contact dermatitis nickel allergy
- Attesting physician’s specialty training in Urology and PUL procedure
Be ready to submit complete medical records on request
If BCBSNC requests medical records, provide full clinical records; letters alone are not sufficient unless they include all specific information needed to make a medical necessity determination.
- Include operative notes, imaging reports (prostate volume), medication history, cancer testing results, and allergy history when requested
Do not rely on letters alone—include all required details
Letters of support or explanation are not sufficient by themselves when records are requested unless they contain every specific data element BCBSNC needs to determine medical necessity.
- If submitting a letter, ensure it contains dates/duration of prior medical therapy, imaging measurement with method, cancer exclusion testing details, allergy status, and provider training statement
Avoid denial by meeting all coverage criteria and not requesting investigational uses
Requests that fail to meet all coverage criteria (for example: age <45, prostate volume >100 cc, no documented trial of medical therapy, presence of prostate cancer, nickel allergy, physician not trained) or that seek investigational uses (repeat PUL, PUL after other minimally invasive BPH procedures, >7 implants) may be denied.
- Investigational/not covered uses include repeat PUL, PUL after other minimally invasive procedures (e.g., transurethral water vapor therapy), PUL in patients with prostate cancer or previously treated for prostate cancer, and use of more than 7 implants
Provide requested records promptly to avoid denial
Failure to provide requested medical records or the specific documentation BCBSNC requests can result in denial of the request for medical necessity.
- Respond promptly to record requests and include the exact data elements cited in the policy to reduce risk of denial
Background and Clinical Context
Benign prostatic hyperplasia (BPH) is a common, age-related enlargement of the prostate that frequently produces lower urinary tract symptoms (LUTS) such as urinary frequency, nocturia, urgency, hesitancy and weak urinary stream; severe or progressive obstruction can lead to urinary retention, infection, or renal compromise. The prostatic urethral lift (PUL, e.g., UroLift System) is a minimally invasive transurethral procedure that places implants to retract prostate lobes and expand the prostatic urethral lumen to relieve obstruction. Symptom severity is commonly measured with validated scores such as the AUASI/IPSS, and the policy applies clinical criteria (including age, prior medical therapy trial, prostate volume, and exclusion of prostate cancer) to determine when PUL is covered.
Definitions and Measurements
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.